Semuloparin (INN, USAN) is an experimental antithrombotic being developed by Sanofi-Aventis and belongs to the group of low molecular weight heparins (LMWH).[1] It has completed Phase III clinical trials for the prevention of thromboembolism following various kinds of surgery such as hip replacement,[2] as well as for patients undergoing chemotherapy.[3]
| Clinical data | |
|---|---|
| Other names | AVE-5026 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| ECHA InfoCard | 100.110.590 |
| Chemical and physical data | |
| Molar mass | 2000–3000 g/mol (average) |
Like bemiparin, semuloparin is classified as an ultra-LMWH because of its low molecular mass of 2000–3000 g/mol on average. (Enoxaparin has 4500 g/mol) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, reducing the risk of bleeding.[4][5]